NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 127 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $222,406 | -80.4% | 207,898 | -52.6% | 0.00% | – |
| Q2 2023 | $1,135,470 | -40.0% | 438,533 | -5.5% | 0.00% | -100.0% |
| Q1 2023 | $1,892,528 | +68769.3% | 463,898 | -15.3% | 0.00% | 0.0% |
| Q4 2022 | $2,748 | -100.0% | 547,865 | -30.5% | 0.00% | -75.0% |
| Q3 2022 | $10,303,000 | +24.3% | 787,808 | +21.8% | 0.00% | +33.3% |
| Q2 2022 | $8,292,000 | -2.8% | 646,718 | +15.6% | 0.00% | 0.0% |
| Q1 2022 | $8,531,000 | +11.1% | 559,339 | +29.0% | 0.00% | +50.0% |
| Q4 2021 | $7,679,000 | +51.2% | 433,607 | +79.4% | 0.00% | 0.0% |
| Q3 2021 | $5,080,000 | +101.9% | 241,721 | +89.5% | 0.00% | +100.0% |
| Q2 2021 | $2,516,000 | -40.2% | 127,557 | -12.2% | 0.00% | 0.0% |
| Q1 2021 | $4,209,000 | +95.8% | 145,264 | +104.8% | 0.00% | 0.0% |
| Q4 2020 | $2,150,000 | +178.9% | 70,932 | +46.5% | 0.00% | – |
| Q3 2020 | $771,000 | +245.7% | 48,432 | +328.0% | 0.00% | – |
| Q2 2020 | $223,000 | – | 11,316 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $59,928,000 | 49.90% |
| Greenspring Associates, LLC | 1,573,357 | $25,032,000 | 38.95% |
| Svennilson Peter | 18,017,932 | $286,665,000 | 23.39% |
| Aquilo Capital Management, LLC | 1,018,334 | $16,202,000 | 1.72% |
| Jasper Ridge Partners, L.P. | 308,750 | $4,912,000 | 0.28% |
| Samsara BioCapital, LLC | 36,451 | $580,000 | 0.16% |
| Rock Springs Capital Management LP | 360,454 | $5,735,000 | 0.15% |
| Point72 Asset Management, L.P. | 1,611,850 | $25,645,000 | 0.13% |
| Virtus ETF Advisers LLC | 14,880 | $237,000 | 0.12% |
| WELD CAPITAL MANAGEMENT LLC | 15,238 | $242,000 | 0.10% |